Compare
OmniAb, Inc. vs MaxCyte, Inc. vs bioAffinity Technologies, Inc. vs Absci Corp
| Latest fiscal year | OmniAb, Inc. OABI | MaxCyte, Inc. MXCT | bioAffinity Technologies, Inc. BIAF | Absci Corp ABSI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $18.67M | $33.03M | $6.16M | $2.80M |
| Revenue growth (YoY) | -29.3% | -14.5% | -34.2% | -38.2% |
| Gross margin | n/a | 81.2% | n/a | n/a |
| Operating margin | -369.5% | -157.1% | -171.6% | n/m |
| Net margin | -347.0% | -135.1% | -242.0% | n/m |
| Net income | -$64.78M | -$44.63M | -$14.91M | -$115.18M |
| EPS (Diluted) | -$0.57 | -$0.42 | -$8.66 | -$0.84 |
| Operating cash flow | -$36.45M | -$34.41M | -$9.33M | -$92.92M |
| Free cash flow | -$37.02M | -$36.18M | -$9.39M | -$94.03M |
| Cash & equivalents | $25.52M | $20.07M | $6.45M | $20.02M |
| Total assets | $300.91M | $202.51M | $10.96M | $216.30M |
| Total liabilities | $33.89M | $31.02M | $3.68M | $26.85M |
| Shareholders' equity | $267.03M | $171.49M | $7.28M | $189.45M |
| Return on year-end equity | -24.3% | -26.0% | -204.9% | -60.8% |
| Shares outstanding | 144.31M | 106.79M | 4.50M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | OmniAb, Inc. | MaxCyte, Inc. | bioAffinity Technologies, Inc. | Absci Corp |
|---|---|---|---|---|
| Latest | $18.67M Ended 2025-12-31 | $33.03M Ended 2025-12-31 | $6.16M Ended 2025-12-31 | $2.80M Ended 2025-12-31 |
| 1 year earlier | $26.39M Ended 2024-12-31 | $38.63M Ended 2024-12-31 | $9.36M Ended 2024-12-31 | $4.53M Ended 2024-12-31 |
| 2 years earlier | $34.16M Ended 2023-12-31 | $41.29M Ended 2023-12-31 | $2.53M Ended 2023-12-31 | $5.72M Ended 2023-12-31 |
| 3 years earlier | $59.08M Ended 2022-12-31 | $44.26M Ended 2022-12-31 | $6.90M Ended 2022-12-31 | $4.53M Ended 2022-12-31 |
| 4 years earlier | $34.75M Ended 2021-12-31 | $33.89M Ended 2021-12-31 | n/a | $4.01M Ended 2021-12-31 |